OncoArendi has received scientific advice from the
'We are very proud to introduce our next molecule into clinical trials. We have just received answers from the
'The fiH (First In Human) study plan and design of our flagship OATD-02 program have been analyzed by the
On 7 February this year,
'The agreement signed today is an important milestone in the beginning clinical development of the OATD-02 compound. We plan to include the first patient in the study in the second half of 2022. The clinical trial itself will last from 18 to 24 months, but the preliminary results in the first groups of patients will be known already in the first half of 2023. We are glad that this key stage of the development of our most advanced project will be supervised and coordinated by experienced specialists in this area - Chief Medical Officer, Dr.
BIOMAPAS was selected by OncoArendi in a competition procedure, the results of which were announced in November last year.
BIOMAPAS will be responsible for organizing a Phase I clinical trial for OATD-02, which will involve up to 40 patients. The clinical trial will be conducted in 3-4 centers in the Polish. Those centres shall be medical entities or specialised early phase clinical trial centres which shall have access to patients, adequate experience, staff and facilities necessary to conduct the clinical trial in question.
OATD-02 is the first in its class and the only dual arginase inhibitor (both ARG1 and ARG2) developed on the market as a potential innovative drug for the treatment of patients with selected forms of advanced cancer. OATD-02 has the potential to unlock the overall immune response in the fight against cancer, as well as strong action inside cancer cells - in the tumor microenvironment. The aim of the clinical trial, during which the compound OTAD-02 will be administered to a human for the first time (the 'First in Human' study), will be to investigate the safety, tolerability and antitumor activity of OATD-02 in patients of both sexes with cancer. This will be a Phase I clinical trial, with increasing doses of the compound administered.
OncoArendi is a clinical-stage drug discovery and delivery biotechnology company that uses its own unique expertise in medical chemistry to seek out and develop best-in-class small-molecule drugs that directly modulate RNA and protein targets in the treatment of many incurable diseases.
OncoArendi's world-class medical chemistry technologies have enabled it to generate a diverse portfolio and nine distinct programs with the support of leading academic scientific institutions around the world, including the
OncoArendi has entered into an exclusive cooperation and license agreement with Galapagos for the global development and commercialization of OncoArendi's OATD-01. OATD-01 is a Phase 2 ready inhibitor of mammalian chitotriosidase/acid chitinase (CHIT1/AMCase) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrosis-related diseases.
OncoArendi's headquarters and laboratories are located in
Detailed information can be found on the LinkedIn https://oncoarendi.com/en/ pages: @OncoArendi Therapeutics | Twitter: @oncoarendi | YouTube: @OncoArendi Therapeutics
Contact:
Media
cc group
Phone: +48 531 613 067
E-mail: michal.wierzchowski@ccgroup.pl
Investors
cc group
Phone: +48 697 613 712
E-mail: katarzyna.mucha@ccgroup.pl
(C) 2022 Electronic News Publishing, source